{"id":"atomoxetine-strattera","safety":{"commonSideEffects":[{"rate":"16-22%","effect":"Decreased appetite"},{"rate":"7-26%","effect":"Nausea"},{"rate":"2-8%","effect":"Dizziness"},{"rate":"16-17%","effect":"Fatigue"},{"rate":"9-16%","effect":"Insomnia"},{"rate":"12-19%","effect":"Headache"},{"rate":"7-16%","effect":"Abdominal pain"},{"rate":"2-6%","effect":"Mood swings / irritability"},{"rate":"1-3%","effect":"Increased blood pressure"},{"rate":"1-2%","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL1702","moleculeType":"Small molecule","molecularWeight":"291.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) that blocks the norepinephrine transporter, preventing the reabsorption of norepinephrine at the presynaptic terminal. This increases norepinephrine concentration in synaptic spaces, particularly in brain regions responsible for attention, impulse control, and executive function. Unlike stimulant medications, it does not directly release norepinephrine or dopamine and has minimal abuse potential.","oneSentence":"Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in the prefrontal cortex and improving attention and executive function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:43.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults"},{"name":"ADHD-related symptoms in patients with comorbid conditions"}]},"trialDetails":[{"nctId":"NCT05350215","phase":"PHASE1, PHASE2","title":"Atomoxetine and DAW2022 on OSA Severity","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-06-01","conditions":"Obstructive Sleep Apnea","enrollment":18},{"nctId":"NCT07316296","phase":"PHASE3","title":"Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-01-01","conditions":"Parkinson's Disease (PD), Freezing of Gait, Freezing of Gait Symptoms in Parkinson Disease","enrollment":60},{"nctId":"NCT06573970","phase":"PHASE4","title":"Atomoxetine and Executive Function in PTSD","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Posttraumatic Stress Disorder With Attention Defic","enrollment":160},{"nctId":"NCT02879136","phase":"EARLY_PHASE1","title":"TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease","status":"COMPLETED","sponsor":"Hubert Fernandez","startDate":"2017-01-03","conditions":"Parkinson's Disease, Idiopathic","enrollment":23},{"nctId":"NCT03919955","phase":"PHASE2","title":"A Novel Pharmacological Therapy for Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-09-03","conditions":"Sleep Apnea","enrollment":117},{"nctId":"NCT05944965","phase":"PHASE1, PHASE2","title":"Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-12-01","conditions":"OSA","enrollment":27},{"nctId":"NCT07280468","phase":"PHASE4","title":"Endotype DIrected Treatment for OSA in Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2026-02-01","conditions":"Obstructive Sleep Apnea (OSA), Down Syndrome","enrollment":200},{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":"Spinal Cord Injuries","enrollment":25},{"nctId":"NCT06295562","phase":"PHASE4","title":"Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2024-11-05","conditions":"Obstructive Sleep Apnea of Adult","enrollment":45},{"nctId":"NCT07251348","phase":"NA","title":"Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Necmettin Erbakan University","startDate":"2026-02-01","conditions":"Hematological Cancer","enrollment":75},{"nctId":"NCT05811247","phase":"PHASE3","title":"Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)","status":"COMPLETED","sponsor":"Apnimed","startDate":"2023-08-28","conditions":"OSA","enrollment":660},{"nctId":"NCT05813275","phase":"PHASE3","title":"Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)","status":"COMPLETED","sponsor":"Apnimed","startDate":"2023-09-16","conditions":"OSA","enrollment":646},{"nctId":"NCT07239791","phase":"NA","title":"Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE)","status":"RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2025-11-18","conditions":"Role of the Noradrenergic System in the Regulation of Learning Dynamics, No Disease or Condition is Being Studied","enrollment":160},{"nctId":"NCT00498173","phase":"PHASE3","title":"Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-07","conditions":"Autism","enrollment":60},{"nctId":"NCT05278104","phase":"NA","title":"A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-09-14","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":63},{"nctId":"NCT00262470","phase":"PHASE1, PHASE2","title":"Treatment of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1997-04","conditions":"Tachycardia, Chronic Orthostatic Intolerance","enrollment":150},{"nctId":"NCT04085172","phase":"PHASE4","title":"A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2019-09-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":396},{"nctId":"NCT04115878","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea In Children With Down Syndrome","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2020-10-21","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":22},{"nctId":"NCT03460210","phase":"","title":"Bariatric Surgery and Pharmacokinetics of Atomoxetine","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-11-02","conditions":"Obesity, Morbid","enrollment":12},{"nctId":"NCT04782830","phase":"NA","title":"Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-05","conditions":"Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure","enrollment":29},{"nctId":"NCT04132557","phase":"","title":"A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":430000},{"nctId":"NCT06566820","phase":"PHASE3","title":"Continuation Protocol for Obstructive Sleep Apnea (OSA)","status":"ENROLLING_BY_INVITATION","sponsor":"Apnimed","startDate":"2024-07-03","conditions":"OSA","enrollment":1280},{"nctId":"NCT04565288","phase":"PHASE2","title":"Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine","status":"COMPLETED","sponsor":"Brown University","startDate":"2021-05-06","conditions":"Alcohol Use Disorder","enrollment":42},{"nctId":"NCT04113551","phase":"","title":"A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":17418},{"nctId":"NCT06899178","phase":"PHASE2","title":"Atomoxetine in Melanocortin Obesity Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-04","conditions":"Melanocortin Obesity Syndrome, MCOS","enrollment":20},{"nctId":"NCT06841666","phase":"EARLY_PHASE1","title":"Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-02-28","conditions":"ADHD, Primary Nocturnal Enuresis","enrollment":100},{"nctId":"NCT06400615","phase":"PHASE2","title":"Study That Tests AD109 in Patients Taking GLP-1 Drugs","status":"COMPLETED","sponsor":"Apnimed","startDate":"2024-05-20","conditions":"OSA","enrollment":40},{"nctId":"NCT06232226","phase":"NA","title":"Attention Deficit Hyperactivity Disorder","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-11","conditions":"Attention Deficit Hyperactivity Disorder, Behavior Hyperactive, Behavior Disorders","enrollment":60},{"nctId":"NCT03808740","phase":"PHASE1","title":"Orthostatic Intolerance After Bariatric Surgery","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-07-01","conditions":"Orthostatic Intolerance","enrollment":10},{"nctId":"NCT05351944","phase":"NA","title":"Dialectical Behavioral Therapy Skills for Impulsive Aggression","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2023-05-07","conditions":"Impulsive Aggression, ADHD, Executive Dysfunction","enrollment":66},{"nctId":"NCT05933603","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-09-29","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":36},{"nctId":"NCT03781765","phase":"PHASE4","title":"Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-06-04","conditions":"ADHD, Attention Deficit Hyperactivity Disorder","enrollment":44},{"nctId":"NCT06542887","phase":"PHASE2","title":"Black Seed Oil in ADHD","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-01","conditions":"ADHD","enrollment":60},{"nctId":"NCT05293600","phase":"PHASE1, PHASE2","title":"Rescue Pharmacotherapy for OSA","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-01","conditions":"Obstructive Sleep Apnea","enrollment":70},{"nctId":"NCT05159687","phase":"PHASE3","title":"Study of Atomoxetine in the Prevention of Vasovagal Syncope","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2022-06-01","conditions":"Vasovagal Syncope","enrollment":180},{"nctId":"NCT03936491","phase":"NA","title":"The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-08-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":105},{"nctId":"NCT04354103","phase":"PHASE2","title":"Atomoxetine in Patients With Tourette's Syndrome","status":"TERMINATED","sponsor":"Poitiers University Hospital","startDate":"2022-05-31","conditions":"Tourette Syndrome","enrollment":5},{"nctId":"NCT05550246","phase":"PHASE1, PHASE2","title":"Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2022-05-05","conditions":"Obstructive Sleep Apnea","enrollment":22},{"nctId":"NCT02136147","phase":"","title":"ADHD Medication and Predictors of Treatment Outcome","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-06","conditions":"Attention Deficit Disorder With Hyperactivity (ADHD)","enrollment":632},{"nctId":"NCT00561340","phase":"NA","title":"Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-01-02","conditions":"ADHD","enrollment":29},{"nctId":"NCT00254462","phase":"PHASE4","title":"Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2005-10-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":93},{"nctId":"NCT04445688","phase":"PHASE2","title":"Crossover Trial of AD036 in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Apnimed","startDate":"2020-07-15","conditions":"Obstructive Sleep Apnea","enrollment":62},{"nctId":"NCT02784535","phase":"PHASE2","title":"Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-08-29","conditions":"Neurogenic Orthostatic Hypotension","enrollment":48},{"nctId":"NCT04905979","phase":"PHASE2","title":"Trial of AD113 and Atomoxetine in OSA Patients With Hypertension","status":"COMPLETED","sponsor":"Apnimed","startDate":"2021-07-31","conditions":"Obstructive Sleep Apnea, Hypertension","enrollment":21},{"nctId":"NCT03154359","phase":"","title":"Atomoxetine PBPK-PD Clinical Study","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2017-12-12","conditions":"ADHD","enrollment":51},{"nctId":"NCT05101122","phase":"PHASE1, PHASE2","title":"Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)","status":"COMPLETED","sponsor":"Apnimed","startDate":"2021-10-19","conditions":"Obstructive Sleep Apnea","enrollment":15},{"nctId":"NCT04958460","phase":"PHASE3","title":"Effect of Probiotics on ADHD","status":"COMPLETED","sponsor":"Wang Liang-Jen","startDate":"2020-05-14","conditions":"ADHD, Probiotics, Gut Microbiota","enrollment":150},{"nctId":"NCT04580394","phase":"PHASE2","title":"Crossover Trial of AD109 in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Apnimed","startDate":"2020-10-27","conditions":"Obstructive Sleep Apnea","enrollment":60},{"nctId":"NCT05071612","phase":"PHASE2","title":"Parallel Arm Trial of AD109 and AD504 In Patients With OSA","status":"COMPLETED","sponsor":"Apnimed","startDate":"2021-11-29","conditions":"OSA - Obstructive Sleep Apnea","enrollment":294},{"nctId":"NCT05635318","phase":"NA","title":"Quantitative EEG Neurofeedback as an Add-on Therapy For Attention-deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-01-01","conditions":"ADHD","enrollment":102},{"nctId":"NCT00716274","phase":"PHASE4","title":"Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Attention Deficit Hyperactivity Disorder, Dyslexia","enrollment":110},{"nctId":"NCT00255138","phase":"PHASE3","title":"Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects","status":"WITHDRAWN","sponsor":"Temple University","startDate":"2005-11","conditions":"Cancer, Cognitive Late Effects","enrollment":""},{"nctId":"NCT00176436","phase":"PHASE4","title":"Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2004-02","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT05229627","phase":"","title":"Multimodal Magnetic Resonance Imaging Study on the Neural Mechanisms of Remission in Children With ADHD","status":"UNKNOWN","sponsor":"Peking University Sixth Hospital","startDate":"2016-01","conditions":"ADHD","enrollment":250},{"nctId":"NCT03324581","phase":"PHASE2","title":"The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-11-09","conditions":"Adult Attention Deficit Hyperactivity Disorder","enrollment":239},{"nctId":"NCT00917371","phase":"","title":"The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults ADHD","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":60},{"nctId":"NCT00916786","phase":"","title":"Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-08-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":240},{"nctId":"NCT01244490","phase":"PHASE3","title":"Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2011-01-17","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":338},{"nctId":"NCT01106430","phase":"PHASE3","title":"Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-28","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":267},{"nctId":"NCT00506727","phase":"PHASE4","title":"Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2003-08-05","conditions":"ADHD","enrollment":215},{"nctId":"NCT00557960","phase":"PHASE3","title":"ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2004-02-25","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":36},{"nctId":"NCT00529893","phase":"","title":"Efficacy of Atomoxetine in the Neuropsychological Tests Among Children With ADHD","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":30},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT00918567","phase":"PHASE4","title":"Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2007-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":56},{"nctId":"NCT00628394","phase":"PHASE4","title":"Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-09","conditions":"Cognition in Schizophrenia","enrollment":119},{"nctId":"NCT01678209","phase":"PHASE4","title":"Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2012-10","conditions":"Attention Deficit Hyperactivity Disorder, ADHD","enrollment":127},{"nctId":"NCT04469335","phase":"NA","title":"Effectiveness of a Mobile Neurofeedback for ADHD Youth","status":"UNKNOWN","sponsor":"Seoul National University Childrens Hospital","startDate":"2020-07-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":165},{"nctId":"NCT01340885","phase":"PHASE4","title":"Cognitive Decline in Non-demented PD","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2011-01","conditions":"Parkinson's Disease","enrollment":9},{"nctId":"NCT02500732","phase":"PHASE2","title":"Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-07","conditions":"Vasovagal Syncope","enrollment":57},{"nctId":"NCT03091400","phase":"PHASE2","title":"Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2017-03-16","conditions":"Memory Disorders, Multiple Sclerosis","enrollment":11},{"nctId":"NCT04216186","phase":"PHASE3","title":"Role of Coenzyme Q in ADHD in Children","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2018-11-01","conditions":"ADHD","enrollment":40},{"nctId":"NCT00780650","phase":"EARLY_PHASE1","title":"Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2009-05","conditions":"Type 1 Diabetes","enrollment":56},{"nctId":"NCT01741376","phase":"NA","title":"Progesterone and Atomoxetine for Cocaine Cessation","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2012-11","conditions":"Cocaine Dependence, Nicotine Dependence","enrollment":""},{"nctId":"NCT04065906","phase":"NA","title":"Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-15","conditions":"Neurofeedback, Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":90},{"nctId":"NCT00181766","phase":"PHASE4","title":"Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-12","conditions":"ADHD NOS","enrollment":45},{"nctId":"NCT00161031","phase":"NA","title":"Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2004-04","conditions":"Schizophrenia","enrollment":30},{"nctId":"NCT01522404","phase":"PHASE2","title":"Effects of Atomoxetine in Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-03","conditions":"Mild Cognitive Impairment","enrollment":39},{"nctId":"NCT02430896","phase":"","title":"Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2015-02","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":600},{"nctId":"NCT00218543","phase":"PHASE2","title":"Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-06","conditions":"Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders","enrollment":20},{"nctId":"NCT00142961","phase":"PHASE2","title":"Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2005-10","conditions":"Attention Deficit Disorder With Hyperactivity, Marijuana Abuse","enrollment":2},{"nctId":"NCT00562055","phase":"PHASE2","title":"Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2007-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT03350659","phase":"PHASE4","title":"Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-01-01","conditions":"Neurogenic Orthostatic Hypotension","enrollment":50},{"nctId":"NCT02287038","phase":"PHASE4","title":"Atomoxetine in Veterans With Comorbid ADHD/PTSD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-10-15","conditions":"Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder","enrollment":44},{"nctId":"NCT03220308","phase":"NA","title":"Mindfulness Training for Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Mindful Parenting","status":"COMPLETED","sponsor":"Karakter Kinder- en Jeugdpsychiatrie","startDate":"2016-02-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":103},{"nctId":"NCT01057329","phase":"","title":"Therapeutic Drug Monitoring in Child and Adolescent Psychiatry","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-01","conditions":"Depression, Anorexia Nervosa, ADHD","enrollment":200},{"nctId":"NCT02908529","phase":"PHASE1, PHASE2","title":"Atomoxetine and Oxybutynin in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-09","conditions":"Obstructive Sleep Apnea (OSA)","enrollment":22},{"nctId":"NCT03651856","phase":"PHASE3","title":"Atomoxetine for Freezing of Gait in Parkinson's Disease","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2013-01","conditions":"Parkinson's Disease, Freezing of Gait","enrollment":10},{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)","enrollment":2},{"nctId":"NCT03661788","phase":"PHASE4","title":"Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2016-05","conditions":"ADHD","enrollment":38},{"nctId":"NCT02142140","phase":"NA","title":"Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2012-12","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":326},{"nctId":"NCT01738191","phase":"PHASE2","title":"Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2012-11","conditions":"Parkinson's Disease, Cognitive Impairment","enrollment":30},{"nctId":"NCT02788851","phase":"NA","title":"The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-04","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":70},{"nctId":"NCT00183391","phase":"PHASE4","title":"Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2005-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":232},{"nctId":"NCT01070394","phase":"PHASE4","title":"Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2010-02","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":40},{"nctId":"NCT00286949","phase":"NA","title":"Treatment of Executive Dysfunction in Parkinson's Disease","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2005-01-06","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT00488163","phase":"PHASE4","title":"Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia","status":"COMPLETED","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2005-01","conditions":"Schizophrenia","enrollment":20},{"nctId":"NCT00617201","phase":"PHASE2","title":"Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial","status":"COMPLETED","sponsor":"Sharon Walsh","startDate":"2007-07","conditions":"Substance Abuse","enrollment":50},{"nctId":"NCT02788357","phase":"PHASE2","title":"Post-stroke Neural Plasticity With Atomoxetine","status":"COMPLETED","sponsor":"Lumy Sawaki","startDate":"2006-11","conditions":"Atomoxetine Hydrochloride, Placebos","enrollment":12},{"nctId":"NCT01498549","phase":"NA","title":"Cognitive Effects of Atomoxetine in Humans: Genetic Moderators","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-12","conditions":"Addiction","enrollment":35},{"nctId":"NCT00418262","phase":"PHASE3","title":"Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2005-08","conditions":"Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":27}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CONSTIPATION"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"INSOMNIA"},{"count":2,"reaction":"MUSCLE SPASMS"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PARAESTHESIA"},{"count":2,"reaction":"POLLAKIURIA"},{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"ABNORMAL BEHAVIOUR"}],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atomoxetine (Strattera)","genericName":"Atomoxetine (Strattera)","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in the prefrontal cortex and improving attention and executive function. Used for Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults, ADHD-related symptoms in patients with comorbid conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}